Takaomi Kessoku

Dr. Takaomi Kessoku

Palliative medicine, International University of Health and Welfare, Chiba, Japan
+1
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Gastroenterology
Verified
Journal Article
Open access
PDF file
KIKento Imajo
Kento Imajo
TKTakaomi Kessoku
Takaomi Kessoku
YHYasushi Honda
Yasushi Honda
WTWataru Tomeno
Wataru Tomeno
YOYuji Ogawa
Yuji Ogawa
Atsushi  NakajimaAtsushi Nakajima
Atsushi Nakajima
Background & Aims Noninvasive methods have been evaluated for the assessment of liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease (NAFLD). We compared the ability of transient elastography (TE) with the M-probe, and magnetic resonance elastography (MRE) to assess liver fibrosis. Findings from magnetic resonance imaging (MRI)−based proton density fat fraction (PDFF) measurements were compared with those from TE-based controlled attenuation parameter (CAP) measurements to assess steatosis. Methods We performed a cross-sectional study of 142 patients with NAFLD (identified by liver biopsy; mean body mass index, 28.1 kg/m2) in Japan from July 2013 through April 2015. Our study also included 10 comparable subjects without NAFLD (controls). All study subjects were evaluated by TE (including CAP measurements), MRI using the MRE and PDFF techniques. Results TE identified patients with fibrosis stage ≥2 with an area under the receiver operating characteristic (AUROC) curve value of 0.82 (95% confidence interval [CI]: 0.74−0.89), whereas MRE identified these patients with an AUROC curve value of 0.91 (95% CI: 0.86−0.96; P = .001). TE-based CAP measurements identified patients with hepatic steatosis grade ≥2 with an AUROC curve value of 0.73 (95% CI: 0.64−0.81) and PDFF methods identified them with an AUROC curve value of 0.90 (95% CI: 0.82−0.97; P < .001). Measurement of serum keratin 18 fragments or alanine aminotransferase did not add value to TE or MRI for identifying nonalcoholic steatohepatitis. Conclusions MRE and PDFF methods have higher diagnostic performance in noninvasive detection of liver fibrosis and steatosis in patients with NAFLD than TE and CAP methods. MRI-based noninvasive assessment of liver fibrosis and steatosis is a potential alternative to liver biopsy in clinical practice. UMIN Clinical Trials Registry No. UMIN000012757.

1 April 2016 in The Lancet Oncology
Verified
Journal Article
Closed access
THTakuma Higurashi
Takuma Higurashi
KHKunihiro Hosono
Kunihiro Hosono
HTHirokazu Takahashi
Hirokazu Takahashi
YKYasuhiko Komiya
Yasuhiko Komiya
SUShotaro Umezawa
Shotaro Umezawa
Atsushi  NakajimaAtsushi Nakajima
Atsushi Nakajima

5 January 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YHYasushi Honda
Yasushi Honda
KIKento Imajo
Kento Imajo
TKTakayuki Kato
Takayuki Kato
TKTakaomi Kessoku
Takaomi Kessoku
YOYuji Ogawa
Yuji Ogawa
Atsushi  NakajimaAtsushi Nakajima
Atsushi Nakajima
In recent years, nonalcoholic steatohepatitis (NASH) has become a considerable healthcare burden worldwide. Pathogenesis of NASH is associated with type 2 diabetes mellitus (T2DM) and insulin resistance. However, a specific drug to treat NASH is lacking. We investigated the effect of the selective sodium glucose cotransporter 2 inhibitor (SGLT2I) ipragliflozin on NASH in mice. We used the Amylin liver NASH model (AMLN), which is a diet-induced model of NASH that results in obesity and T2DM. AMLN mice were fed an AMLN diet for 20 weeks. SGLT2I mice were fed an AMLN diet for 12 weeks and an AMLN diet with 40 mg ipragliflozin/kg for 8 weeks. AMLN mice showed steatosis, inflammation, and fibrosis in the liver as well as obesity and insulin resistance, features that are recognized in human NASH. Ipragliflozin improved insulin resistance and liver injury. Ipragliflozin decreased serum levels of free fatty acids, hepatic lipid content, the number of apoptotic cells, and areas of fibrosis; it also increased lipid outflow from the liver. Ipragliflozin improved the pathogenesis of NASH by reducing insulin resistance and lipotoxicity in NASH-model mice. Our results suggest that ipragliflozin has a therapeutic effect on NASH with T2DM.

14 February 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YHYasushi Honda
Yasushi Honda
TKTakaomi Kessoku
Takaomi Kessoku
YOYuji Ogawa
Yuji Ogawa
WTWataru Tomeno
Wataru Tomeno
KIKento Imajo
Kento Imajo
Atsushi  NakajimaAtsushi Nakajima
Atsushi Nakajima
The efficacy of peroxisome proliferator-activated receptor α-agonists (e.g., fibrates) against nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) in humans is not known. Pemafibrate is a novel selective peroxisome proliferator-activated receptor α modulator that can maximize the beneficial effects and minimize the adverse effects of fibrates used currently. In a phase-2 study, pemafibrate was shown to improve liver dysfunction in patients with dyslipidaemia. In the present study, we first investigated the effect of pemafibrate on rodent models of NASH. Pemafibrate efficacy was assessed in a diet-induced rodent model of NASH compared with fenofibrate. Pemafibrate and fenofibrate improved obesity, dyslipidaemia, liver dysfunction, and the pathological condition of NASH. Pemafibrate improved insulin resistance and increased energy expenditure significantly. To investigate the effects of pemafibrate, we analysed the gene expressions and protein levels involved in lipid metabolism. We also analysed uncoupling protein 3 (UCP3) expression. Pemafibrate stimulated lipid turnover and upregulated UCP3 expression in the liver. Levels of acyl-CoA oxidase 1 and UCP3 protein were increased by pemafibrate significantly. Pemafibrate can improve the pathogenesis of NASH by modulation of lipid turnover and energy metabolism in the liver. Pemafibrate is a promising therapeutic agent for NAFLD/NASH.

29 October 2021 in Frontiers in Endocrinology
Verified
Journal Article
Open access
TKTakaomi Kessoku
Takaomi Kessoku
TKTakashi Kobayashi
Takashi Kobayashi
KIKento Imajo
Kento Imajo
KTKosuke Tanaka
Kosuke Tanaka
AYAtsushi Yamamoto
Atsushi Yamamoto
ANAtsushi Nakajima
Atsushi Nakajima
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. It occurs with a prevalence of up to 25%, of which 10–20% cases progress to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. The histopathology of NASH is characterized by neutrophilic infiltration, and endotoxins from gram-negative rods have been postulated as a contributing factor. Elevations in endotoxin levels in the blood can be classified as intestinal and hepatic factors. In recent years, leaky gut syndrome, which is characterized by impaired intestinal barrier function, has become a significant issue. A leaky gut may prompt intestinal bacteria dysbiosis and increase the amount of endotoxin that enters the liver from the portal vein. These contribute to persistent chronic inflammation and progressive liver damage. In addition, hepatic factors suggest that liver damage can be induced by low-dose endotoxins, which does not occur in healthy individuals. In particular, increased expression of CD14, an endotoxin co-receptor in the liver, may result in leptin-induced endotoxin hyper-responsiveness in obese individuals. Thus, elevated blood endotoxin levels contribute to the progression of NASH. The current therapeutic targets for NASH treat steatosis and liver inflammation and fibrosis. While many clinical trials are underway, no studies have been performed on therapeutic agents that target the intestinal barrier. Recently, a randomized placebo-controlled trial examined the role of the intestinal barrier in patients with NAFLD. To our knowledge, this study was the first of its kind and study suggested that the intestinal barrier may be a novel target in the future treatment of NAFLD.

26 January 2015 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
WTWataru Tomeno
Wataru Tomeno
KKKeigo Kawashima
Keigo Kawashima
MYMasato Yoneda
Masato Yoneda
SSSatoru Saito
Satoru Saito
YOYuji Ogawa
Yuji Ogawa
Atsushi  NakajimaAtsushi Nakajima
Atsushi Nakajima